Two Biopharmaceutical Organizations Award More Than $1.4 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring
March 31 2004 - 9:05AM
PR Newswire (US)
Two Biopharmaceutical Organizations Award More Than $1.4 Million in
Studies to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Two Thorough Phase I ECG Studies
Include New Study Design and Baseline Study Capable of Extension
PHILADELPHIA, March 31 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT) , a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has received agreements for more than $1.4
million in cardiac safety monitoring and services from a top 50
pharmaceutical and growing biotechnology organization for two drug
candidates in clinical development. The agreements cover two
extensive Phase I studies for which eRT is providing comprehensive
support including the provision, training and ongoing assistance
required for effective use of digital 12-lead Holter equipment
designed to facilitate 24-hour digital recording of cardiac safety
data that is subsequently provided to eRT for analysis. eRT will
perform digital collection, measurement, interpretation, review,
and distribution of cardiac safety data through its EXPeRT workflow
enabled data handling technology, the first solution in production
thatwas designed explicitly to meet emerging international
regulatory guidance and technical standards. The studies are
targeted for completion over a 90-day period. "We are excited by
eRT having been selected to provide comprehensive cardiac safety
services for these Thorough Phase I ECG studies, each of which
provides a unique opportunity to marry eRT's capabilities with
sponsor requirements," said Scott Grisanti, senior vice president
of business development and chief marketing officer at eRT.
"Thefirst study, which is a pilot being conducted on behalf of a
global top 50 pharmaceutical organization, is advancing a key
aspect of study design that will provide more flexibility to the
entire industry. The second study is being conducted for an
emerging biotechnology organization, which is leveraging eRT's
digital Holter platform to provide the flexibility to add 12-lead
ECG time points for analysis at any time during or after conduct of
the study with determination of an optimal ECG collection profile."
Based in Philadelphia, PA, eResearchTechnology, Inc.
(http://www.ert.com/) is a provider of technology and services to
the pharmaceutical, biotechnology and medical device industries on
a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
The sponsors may cancel these agreements at their sole discretion.
As a result, actual results may differ materially from any
financial outlooks stated herein. Further information on potential
factors that could affect the company's financial results can be
found in the company's Reports on Forms 10-K and 10-Q filed with
the Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles